Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in mice
Preprint
Abstract
Post-antibiotic effect (PAE) describes the delayed recovery of bacteria following antibiotic exposure. PAE is thought to underlie tuberculosis (TB) treatment forgiveness, i.e. the capacity of regimens to tolerate non-adherence. The basis of PAE in Mycobacterium tuberculosis ( Mtb ) remains poorly understood, partly because PAE has conventionally been measured based on change in Mtb burden in vitro rather than change in Mtb physiology in vivo . We investigated Mtb physiologic recovery in the BALB/c mouse model following sub-curative 2- and 4-week durations of the standard isoniazid, rifampin, pyrazinamide, ethambutol (HRZE) treatment. Measurement of rRNA synthesis via the RS ratio® and the entire transcriptome via SEARCH-TB elucidated the dynamics of physiologic recovery. Mtb burden did not increase over 28 days of drug-free post-treatment recovery, indicating prolonged PAE in vivo. The RS ratio indicated that Mtb ribosomal RNA synthesis resumed within four days of treatment interruption. However, transcriptional changes indicative of metabolic reactivation were delayed for over two weeks. Processes critical for replication, including expression of genes involved in protein and cell wall synthesis, remained suppressed throughout 28 days post-treatment. Longer treatment induced more extensive physiologic perturbation and was associated with slower and less complete recovery. Expression of processes that are typically induced by environmental stress ( e.g. , DosR regulon, universal stress proteins, and heat shock proteins) exhibited the reverse, decreasing during drug treatment and rising during recovery. These findings provide a new basis for understanding PAE based on drug-induced injury and physiologic recovery. Following relatively short durations of HRZE, physiologic recovery of Mtb was a slow, sequential and incomplete process in vivo. Our observation that longer treatment resulted in even slower recovery suggests that Mtb may progressively lose capacity to recover. This work establishes a tractable experimental framework for quantifying the forgiveness of new TB treatment regimens in vivo .Keywords
This publication has 47 references indexed in Scilit:
- Study of drug interaction, mutant frequency and mutant prevention concentration of DFMBT against Mycobacterium tuberculosis H37RVMicrobial Pathogenesis, 2023
- Translational Model‐Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical DevelopmentClinical Pharmacology & Therapeutics, 2020
- Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction ModelsCPT: Pharmacometrics & Systems Pharmacology, 2017
- Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ MiceACS Infectious Diseases, 2016
- Pharmacokinetics and Pharmacodynamics of Anti-infective Agents2015
- Ward’s Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward’s Criterion?Journal of Classification, 2014
- Mycobacterium tuberculosis Senses Host-Derived Carbon Monoxide during Macrophage InfectionCell Host & Microbe, 2008
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- The postantibiotic effectClinical Microbiology Newsletter, 1991
- The bactericidal action of penicillin on Staphylococcus pyogenesIrish Journal of Medical Science (1971 -), 1944